Vamifeport reduced hemolysis in HbSS mice. Vamifeport significantly reduced plasma markers of hemolysis in HbSS mice, including heme (A), lactate dehydrogenase (LDH) (B), and indirect bilirubin (C). (D) Erythrophagocytosis was reduced in HbSS mice treated with vamifeport, as shown by percentages of Ter119⁺ red pulp macrophages, identified by gating on CD45⁺F4/80⁺ spleen cells. (E) Total iron deposition in the kidneys of HbSS mice was reduced by vamifeport, as measured by inductively coupled plasma optical emission spectrometry. (F) Reduction of total iron deposition in the kidneys of HbSS mice by vamifeport was also illustrated by Perls staining of kidney sections. Results are presented as individual values with mean ± standard deviation (n = 5-8 mice per group). Analysis was performed by using one-way analysis of variance with Dunnett’s multiple comparison of all groups vs the HbSS vehicle group: *P < .05, **P < .01, ***P < .001. Abs, absorbance; BID, twice daily.